The day before the opening today of the ASH conference in Atlanta, TG Therapeitics announced it has initiated a phase 1 and 2 clinical trials to evaluate the safety, tolerability and efficacy of its product, TG-1101, a novel third-generation anti-CD20 monoclonal antibody, in combination with Revilimid for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.
As a result of this exercise, 1205 MSM and TG people have registered to become official members of the network and nearly 100 of them have expressed their interests to be candidates for the new Executive Committee.
Reputable restaurants and chefs use TG in the preparation of some menu items when they are cooking or reassembling a meat preparation that has been deconstructed in order to cook it properly.